What Is ABBV Fair Value?
AbbVie Inc. (ABBV) fair value estimate using multiple valuation models, updated daily.
As of September 15, 2026, AbbVie Inc. (ABBV) has a composite fair value estimate of $1,127.55 based on four valuation models: DCF (47% weight), Graham Number (0% weight), PEG (33% weight), and DDM (20% weight). The current market price is $263.04, suggesting the stock is undervalued by 328.7%.
Data as of September 15, 2026 (today)
Composite Fair Value
Undervalued3 of 4 models$1,127.55
vs. current price of $263.04(+328.7%)
How Is ABBV Fair Value Calculated?
Four independent models estimate what ABBV is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ABBV Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
47% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$1,549.48
+489.1%Undervalued
Inputs used
DDM (Dividend Discount Model)
20% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$726.91
+176.4%Undervalued
Inputs used
ABBV Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
0% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
N/A
Requires positive EPS and book value. AbbVie Inc. currently has negative earnings, so the Graham formula cannot be applied.
Inputs used
PEG (Price/Earnings to Growth)
33% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$394.40
+49.9%Undervalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $263.04 is 489.1% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $21.09B | $19.94B |
| Year 2 | $26.36B | $23.56B |
| Year 3 | $32.95B | $27.85B |
| Year 4 | $41.19B | $32.91B |
| Year 5 | $51.48B | $38.90B |
| Year 6 | $64.35B | $45.97B |
| Year 7 | $80.44B | $54.33B |
| Year 8 | $100.55B | $64.20B |
| Year 9 | $125.69B | $75.88B |
| Year 10 | $157.12B | $89.67B |
| Terminal Value | $4.93T | $2.81T |
What Are ABBV's Key Financial Metrics?
Earnings & Growth
Current Price
$263.04
EPS (TTM)
$3.53
Forward P/E
16.2
Profit Margin
9.8%
Cash & Balance Sheet
Free Cash Flow
16.9B
EBITDA
30.8B
Book Value
-$3.36
Total Debt
70.9B
What Do Analysts Say About ABBV?
Low
$200.00
Average
$278.61
High
$328.00
Upside
+5.9%
ABBV Fair Value FAQ
What is the fair value of ABBV?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ABBV's estimated fair value is $1,127.55. The stock is currently trading at $263.04, which makes it undervalued by our analysis.
How is ABBV's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ABBV overvalued or undervalued?
Based on our analysis, ABBV is undervalued. The current price of $263.04 is 328.7% below our estimated fair value of $1,127.55.
What do Wall Street analysts say about ABBV?
28 analysts cover AbbVie Inc. with a consensus rating of "Buy." The average price target is $278.61, ranging from $200.00 to $328.00. This implies 5.9% upside from the current price.